Who
Yann Mazabraud
EVP, Head of International
Company insider
Files Form 4 as: EVP, Head of International, Rhythm Pharmaceuticals; Officer, Trevi Therapeutics.
In numbers
- Trades disclosed
- 86
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $19.5M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 Jun 2019
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $317K46,625 at $6.80 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $257K2,300 at $111.80 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $113K1,000 at $112.86 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —46,625 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $413K3,605 at $114.70 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.7M14,568 at $115.43 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.1M18,208 at $116.49 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.0M17,319 at $117.47 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —46,625 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $317K46,625 at $6.80 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $257K2,300 at $111.80 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $113K1,000 at $112.86 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $413K3,605 at $114.70 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.7M14,568 at $115.43 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.1M18,208 at $116.49 | filing |
| 12 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.0M17,319 at $117.47 | filing |
| 1 Apr 2026filed 3 Apr 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —12,875 | filing |
| 1 Apr 2026filed 3 Apr 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,375 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,375 at $0.00 | filing |
News
Contrasting Rhythm Pharmaceuticals (NASDAQ:RYTM) & ADMA Biologics (NASDAQ:ADMA)RYTM · dailypolitical.com · 22 Oct 2026Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Yann Mazabraud; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.